Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0003240
UniProt IDP47985
Primary gene name(s)UQCRFS1
Synonym gene name(s)unknown
Protein nameCytochrome b-c1 complex subunit Rieske, mitochondrial
Protein functionComponent of the ubiquinol-cytochrome c reductase complex, complex III or cytochrome b-c1 complex, which is a respiratory chain that generates an electrochemical potential coupled to ATP synthesis.; FUNCTION: The transit peptide of the Rieske protein seems to form part of the bc1 complex and is considered to be the subunit 11/IX of that complex. {ECO:0000250}.
Subcellular locationMitochondrion inner membrane;
Single-pass membrane protein.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P47985
Gene Ontology
(Biological Process)
Complete annatation
mitochondrial electron transport, ubiquinol to cytochrome c [GO:0006122];
response to antibiotic [GO:0046677];
response to drug [GO:0042493];
response to hormone [GO:0009725]
Gene Ontology
(Molecular Function)
Complete annatation
2 iron, 2 sulfur cluster binding [GO:0051537];
metal ion binding [GO:0046872];
ubiquinol-cytochrome-c reductase activity [GO:0008121]
Gene Ontology
(Cellular Component)
Complete annatation
mitochondrial inner membrane [GO:0005743];
mitochondrial respiratory chain complex III [GO:0005750];
mitochondrion [GO:0005739];
myelin sheath [GO:0043209]
Protein-protein interaction113232
Phylogenetic treeP47985
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD31.252832847853240.0001707840780683640.000772758218146619
AZA vs. DISU-0.1506289429988090.5528507639625390.947322379942551
AZA vs. IL70.1666737592753180.3889457900403170.999311006273513
AZA vs. SAHA-0.120206127193640.6235859794499160.879493809379627
DISU vs. CD3-1.415536161614590.0001298225939596610.000712931734950457
DISU vs. IL70.3084210077901680.2224048916613690.60475356092986
DISU vs. SAHA0.0316830741352650.9135925928600460.98055132615251
DMSO vs. AZA-0.09363869312685360.5798372366494831
DMSO vs. CD3-1.358511014409743.11316290797503e-050.000158552397595145
DMSO vs. DISU0.05491078368819850.8225022522728860.980295078677667
DMSO vs. IL70.2677628677767190.1392530079598960.638437989090265
DMSO vs. SAHA-0.03301689564364820.8890497106702260.972686978140092
HIV vs. Mock in Activation-0.2021185585753670.7452738700402760.999983755607037
HIV vs. Mock in Latency-0.05387108875060670.746204512991450.999834320637052
IL7 vs. CD3-1.077922286077510.0009148603440829460.0039286866001032
SAHA vs. CD3-1.397502861959350.000107197698135830.00051252198950094
SAHA vs. IL7-0.290187291837870.2353685991391710.476234397775015
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.0772904 0.648631
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.054 1.095 1.227 1.199 1.049
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB07401 METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE experimental unknown unknown
DB04141 2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol experimental unknown unknown
DB07636 5-HEPTYL-6-HYDROXY-1,3-BENZOTHIAZOLE-4,7-DIONE experimental unknown unknown
DB07763 (5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE experimental unknown unknown
DB07778 FAMOXADONE experimental unknown unknown
DB08330 METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE experimental unknown unknown
DB08453 2-NONYL-4-HYDROXYQUINOLINE N-OXIDE experimental unknown unknown
DB04799 5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole experimental unknown unknown
DB08690 UBIQUINONE-2 experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

not found

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
HIV-1 virus replication enhanced by expression of human gene 18854154

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa00190 Oxidative phosphorylation - Homo sapiens (human)
hsa01100 Metabolic pathways - Homo sapiens (human)
hsa04260 Cardiac muscle contraction - Homo sapiens (human)
hsa04932 Non-alcoholic fatty liver disease (NAFLD) - Homo sapiens (human)
hsa05010 Alzheimer's disease - Homo sapiens (human)
hsa05012 Parkinson's disease - Homo sapiens (human)
hsa05016 Huntington's disease - Homo sapiens (human)